PTJ
ECYT

Paul Tudor Jones’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Paul Tudor Jones’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-37,400
Closed -$246K – 1557
2014
Q2 		$246K Sell
37,400
-12,600
-25% -$142K 0.01% 935
2014
Q1 		$1.19M Buy
50,000
+33,256
+199% +$482K 0.05% 155
2013
Q4 		$179K Buy
+16,744
New +$185K 0.01% 1126

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Paul Tudor Jones's ECYT Position: Q3 2014 in Review

Paul Tudor Jones sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2014, closing a stake of 37,400 shares — an estimated $246K sold.

Paul Tudor Jones first reported a position in ECYT in Q4 2013 and held it in 3 quarters. The position peaked at $1.19M in Q1 2014. 101 funds tracked by Wall St. Rank hold ECYT as of Q3 2014.

  • Paul Tudor Jones reported no remaining Endocyte, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Paul Tudor Jones sold 37,400 Endocyte, Inc. Common Stock shares in Q3 2014, an estimated $246K.
  • Paul Tudor Jones first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 3 quarters.
  • Paul Tudor Jones's Endocyte, Inc. Common Stock position peaked at $1.19M in Q1 2014.
  • 101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2014.

Based on Tudor Investment Corp's 13F filing for Q3 2014, filed 14 Nov 2014.